ESPEROCT

Google image searchProduct monograph

Active ingredient

antihemophilic factor viii (recombinant, b-domain truncated), pegylated, 2000 UNIT/VIAL

DIN: 02490099

Dosage form(s): POWDER FOR SOLUTION

Route(s) of administration: INTRAVENOUS

Schedule: Schedule D

Company: NOVO NORDISK CANADA INC

Date: 10-MAR-2022

ATC:

• B02 — ANTIHEMORRHAGICS (ATC, ATC/DDD, )
• B02B — VITAMIN K AND OTHER HEMOSTATICS (ATC, ATC/DDD)
• B02BD — Blood coagulation factors (ATC, ATC/DDD)
• B02BD02 — COAGULATION FACTOR VIII (ATC/DDD)

Reference brand drug: Adynovate, Eloctate, Esperoct, Jivi, Kovaltry, Nuwiq, Obizur, Xyntha, Zonovate

Pharmaceutical standard: MFR

External Links for Esperoct

Search on Google

• Esperoct side effects
• Esperoct dosage
• antihemophilic factor viii side effects
• antihemophilic factor viii dosage

Novo Nordisk Canada Inc

Go to Novo Nordisk website to see drug product details. Sometimes you can find esperoct photos and/or monograph. If you are a healthcare professional, you may need to enter your license number.